A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2017-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.16m11216PMID 28858444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer’s disease

  2017cited by this paper
• A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease

  2016cited by this paper
• Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.

  2015cited by this paper
• Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study.

  2015cited by this paper
• Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

  2015cited by this paper
• Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

  2015cited by this paper
• Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights

  2014cited by this paper
• Clinical pharmacology of atypical antipsychotics: an update

  2014cited by this paper
• Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease

  2014cited by this paper
• Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography

  2014cited by this paper
• Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis

  2013cited by this paper
• A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

  2013cited by this paper
• Establishing Test–Retest Reliability of an Adapted [18F]Fallypride Imaging Protocol in Older People

  2013cited by this paper
• Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study.

  2012cited by this paper
• Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010

  2012cited by this paper
• Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

  2011cited by this paper
• All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

  2011cited by this paper
• Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis

  2011cited by this paper
• The Blood–Brain Barrier: Geriatric Relevance of a Critical Brain–Body Interface

  2010cited by this paper
• Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms.

  2009cited by this paper
• Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.

  2009cited by this paper
• Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring

  2009cited by this paper
• Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride

  2008cited by this paper
• Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

  2008cited by this paper
• Sex, Race, and Smoking Impact Olanzapine Exposure

  2008cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine

  2006cited by this paper
• Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride

  2005cited by this paper
• Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies

  2004cited by this paper
• High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

  2004cited by this paper
• Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.

  2003cited by this paper
• A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

  2002cited by this paper
• Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

  2002cited by this paper
• In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia

  2001cited by this paper
• Potentials and Pitfalls Using High Affinity Radioligands in PET and SPET Determinations on Regional Drug Induced D2 Receptor Occupancy - A Simulation Study Based on Experimental Data

  2001cited by this paper
• Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome.

  2000cited by this paper
• The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum.

  2000cited by this paper
• Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers

  1998cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors.

  1996cited by this paper
• The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

  1995cited by this paper
• Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.

  1995cited by this paper
• Imaging endogenous dopamine competition with [11C]raclopride in the human brain

  1994cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Modeling the Double Peak Phenomenon in Drug Absorption Kinetics: The Case of Amisulpride

  2023cites this paper
• Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies

  2023cites this paper
• Study on the relationship among dose, concentration and clinical response in Chinese schizophrenic patients treated with Amisulpride.

  2021cites this paper
• Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level

  2021cites this paper
• DDDT_A_327506 3903..3913

  2021cites this paper
• Towards safer risperidone prescribing in Alzheimer's disease

  2020cites this paper
• Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses

  2019cites this paper
• Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls: impact on translational drug development

  2019cites this paper
• Amisulpride

  2019cites this paper
• Psychotic disorders in late life: a narrative review

  2019cites this paper
• Management of antipsychotic related hyperprolactinemia in older people: Can we extrapolate from existing guidance?

  2018cites this paper
• Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review

  2018cites this paper